Establishment and characterization of osseous prostate cancer models: Intra tibial injection of human prostate cancer cells

被引:144
作者
Corey, E
Quinn, JE
Bladou, F
Brown, LG
Roudier, MP
Brown, JM
Buhler, KR
Vessella, RL
机构
[1] Univ Washington, Dept Urol, Seattle, WA 98195 USA
[2] Hop Salvator, Marseille, France
[3] VA Puget Sound Hlth Care Syst, Seattle, WA USA
关键词
prostate cancer; bone metastasis; osteoblastic response; osteolytic response; animal model;
D O I
10.1002/pros.10091
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. To improve the therapy of advanced prostate cancer (CaP), it is critical to develop animal models that mimic Cap bone metastases. Unlike the human disease, CaP xenograft models rarely metastasize spontaneously to bone from the orthotopic site of primary tumor growth. METHODS. Single-cell suspensions of LNCaP, PC-3, LuCaP 35, and LuCaP 23.1 CaP cells were injected directly into tibia of SCID mice. Immunohistochemistry and bone histomorphometrical analyses were performed to characterize these osseous-CaP models. RESULTS. LuCaP 23.1 Yields an osteoblastic response, LNCaP Yields mixed lesions, and LuCaP 35 and PC-3 result in osteolytic responses. We have detected osteoprotegerin, RANK ligand, parathyroid hormone-related protein, and endothelin-1, proteins associated with bone growth and remodeling, in the CaP cells grown in the bone. CONCLUSIONS. These animal models can be used to study biological interactions, pathways, and potential therapeutic targets, and also to evaluate new agents for treatment and prevention of CaP bone metastasis. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:20 / 33
页数:14
相关论文
共 52 条
[21]  
HARADA M, 1992, ADV EXP MED BIOL, V324, P173
[22]  
HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809
[23]   Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer [J].
Ikeda, I ;
Miura, T ;
Kondo, I .
BRITISH JOURNAL OF UROLOGY, 1996, 77 (01) :102-106
[24]   Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors [J].
Itoh, K ;
Udagawa, N ;
Matsuzaki, K ;
Takami, M ;
Amano, H ;
Shinki, T ;
Ueno, Y ;
Takahashi, N ;
Suda, T .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (09) :1766-1775
[25]   Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen [J].
Iwamura, M ;
Hellman, J ;
Cockett, ATK ;
Lilja, H ;
Gershagen, S .
UROLOGY, 1996, 48 (02) :317-325
[26]  
KAIGHN ME, 1979, INVEST UROL, V17, P16
[27]  
Kaul KL, 1998, J UROLOGY, V159, P292
[28]  
Koeneman KS, 1999, PROSTATE, V39, P246
[29]   Molecular control of bone remodeling and osteoporosis [J].
Kong, YY ;
Penninger, JM .
EXPERIMENTAL GERONTOLOGY, 2000, 35 (08) :947-956
[30]   Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation [J].
Lacey, DL ;
Timms, E ;
Tan, HL ;
Kelley, MJ ;
Dunstan, CR ;
Burgess, T ;
Elliott, R ;
Colombero, A ;
Elliott, G ;
Scully, S ;
Hsu, H ;
Sullivan, J ;
Hawkins, N ;
Davy, E ;
Capparelli, C ;
Eli, A ;
Qian, YX ;
Kaufman, S ;
Sarosi, I ;
Shalhoub, V ;
Senaldi, G ;
Guo, J ;
Delaney, J ;
Boyle, WJ .
CELL, 1998, 93 (02) :165-176